Menus Subscribe Search

Genes Are Us

pencil-dna

(Photo: Lightspring/Shutterstock)

The FDA Is Not Anti-Genetics

• January 17, 2014 • 12:00 PM

(Photo: Lightspring/Shutterstock)

Despite the recent crackdown on 23andMe, the FDA is engaging with fast-moving biotechnology advances. However, there’s still much work to be done.

When the FDA shut down biotech company 23andMe’s direct-to-consumer Personal Genome Service, many in the biotech community worried that the FDA was risking the survival of a nascent industry that would revolutionize medical care with new genetic technologies. But lost in the story about 23andMe was the news that the FDA had just issued its very first approval for a next-generation DNA analysis machine, clearly signaling that the agency recognizes the growing significance of genetic testing in medicine.

The FDA approved a machine called the MiSeqDx, “the first FDA-regulated test system that allows laboratories to develop and validate sequencing of any part of a patient’s genome.” For a few hundred dollars, this little machine can analyze an amount of DNA in 24 hours that, 10 years ago, would have taken a dozen machines two weeks and cost nearly a million dollars. The rate of improvement in our technical capacity to read out DNA has been stunningly rapid, outpacing even the expectations of Moore’s Law, the gold standard for progress in the computer industry. Biomedical researchers can now consider ways to bring DNA analysis into the clinic that would have been impossible before. Rather than testing for mutations in one gene at a time, and in only very specific groups of patients, it’s becoming feasible to scan much larger portions of a patient’s DNA as part of a routine health assessment for everyone. What’s happening in medical genetics is the equivalent of having the operating costs of a private jet suddenly drop to those of a Honda Civic—in which case you’d probably start considering previously unthinkable destinations for not only the annual family vacation, but for three-day weekends as well.

In a report issued last fall (PDF), the FDA laid out its view of the regulatory challenges posed by personalized genetic medicine. At issue is the idea that with cheap, accessible DNA analysis, medical care can be personalized to match each person’s genetic makeup. Cancer diagnoses, rather than being based on abnormalities that are visible under a microscope, would instead be classified more effectively by their underlying genetic mutations. The typical trial-and-error approach to find the right drug for a patient suffering from depression would give way to a genetic test that would indicate the best drug.

Does the FDA need to protect you from information about your genome, especially if some of that information is potentially unreliable? Or should anyone be able to buy a tentative analysis of their genome based on the latest research?

It sounds great in principle, but the result is a major headache for the FDA, because modern genetic medicine is demolishing regulatory concepts and categories that the agency has long used to ensure that drugs and diagnostics are safe and effective.

Take genetic tests for instance. The two primary criteria the FDA uses to evaluate diagnostics are analytical validity and clinical validity. As the FDA report describes them, “analytical validity refers to how well the test measures what it is supposed to measure, whereas clinical validity looks at how well the test predicts who has or does not have a disease or condition for which it is being tested.” A typical diagnostic test is required to be both analytically and clinically valid, but for large-scale genetic tests this doesn’t make sense. Tests that analyze hundreds or thousands of regions of your DNA at once can be analytically valid—that is, they accurately determine the identity of mutations in your genome—but the clinical validity will vary with the individual mutation, depending on whether that mutation has a discernible effect. Furthermore, clinical validity for any one mutation will often be in flux, as new research clarifies the role of poorly understood mutations.

Another challenge with personalization is that a drug and a diagnostic test are more likely to be paired in their development. Some drugs, like the cystic fibrosis drug Kalydeco, are deliberately targeted only at patients with a specific mutation. Pairing genetic tests with therapeutics makes it difficult to track down the source of problems when something doesn’t work. As the FDA report notes, “An adverse event associated with the use of a therapeutic product may have arisen as a result of failure of the test to identify the optimal subset of patients due to design deficiencies, manufacturing deficiencies, or operator error.”

To respond to these challenges, the FDA report describes the changes you’d expect from a large and complex government agency tasked with keeping up with a large and complex industry. There are restructurings, efforts to increase communication and coordination among different agency centers, and committees to rethink the process by which some new treatments and diagnostics are approved.

WHILE THE FDA MAY be making an admirable effort to confront the issues raised in the report, the authors ignored the elephant in the room: the wild frontier of direct-to-consumer genetic testing, represented by 23andMe. Consumer-oriented genome services undermine one of the biggest regulatory concepts that the FDA depends on: whether or not something counts as a medical diagnostic device. Does the FDA need to protect you from information about your genome, especially if some of that information is potentially unreliable? Or should anyone be able to buy a tentative analysis of their genome based on the latest research?

This is where medical genetics shades into recreational genetics. It doesn’t help that these services are often advertised with the dubious claim that they will empower you to take your health into your own hands. As a group of researchers, physicians, and health policy experts noted in a recent commentary, “there is little evidence to support the basic premise implied by the empowerment rhetoric—namely that individuals will use genomic risk information to adopt a healthier lifestyle and, thus, reduce their risk for chronic diseases.”

Even if a personal genome analysis is not useful yet, it is hard to make the case that we should be barred from it. These services feed our curiosity about ourselves, and they are an opportunity to educate consumers about genetics. Of course our genetics are inextricably tied up with our health, which means that direct-to-consumer genetic services will always threaten to impinge on the FDA’s territory. How it should respond is an issue not yet resolved.

Michael White
Michael White is a systems biologist at the Department of Genetics and the Center for Genome Sciences and Systems Biology at the Washington University School of Medicine in St. Louis, where he studies how DNA encodes information for gene regulation. He co-founded the online science pub The Finch and Pea. Follow him on Twitter @genologos.

More From Michael White

A weekly roundup of the best of Pacific Standard and PSmag.com, delivered straight to your inbox.

Recent Posts

July 30 • 4:00 PM

Still the World’s Top Military Spender

Although declining in real terms, the United States’ military budget remains substantial and a huge drain on our public resources.



July 30 • 2:04 PM

The Rise of the Nuisance Flood

Minor floods are afflicting parts of Maryland nearly 10 times more often than was the case in the 1960s.


July 30 • 2:00 PM

The (Mostly Awful) Things You Learn After Investigating Unpaid Internships for a Year

Though the intern economy remains opaque, dialogue about the role of interns in the labor force—and protections they deserve—is beginning to take shape.


July 30 • 12:00 PM

Why Coffee Shortages Won’t Change the Price of Your Frappuccino

You’re so loyal to Starbucks—and the company knows it—that your daily serving of caffeine is already marked up beyond the reach of any fluctuations in supply.



July 30 • 10:00 AM

Having Difficult Conversations With Your Children

Why it’s necessary, and how to do it.


July 30 • 8:00 AM

How to Make a Convincing Sci-Fi Movie on a Tight Budget

Coherence is a good movie, and its initial shoot cost about the same amount of money as a used Prius.


July 30 • 6:00 AM

Are You Really as Happy as You Say You Are?

Researchers find a universal positivity bias in the way we talk, tweet, and write.


July 30 • 4:00 AM

The Declining Wage Gap for Gay Men

New research finds gay men in America are rapidly catching up with straight married men in terms of wages.


July 30 • 2:00 AM

LeBron James Migration: Big Chef Seeking Small Pond

The King’s return to Cleveland is a symbol for the dramatic shift in domestic as well as international migration.


July 29 • 4:00 PM

Are Children Seeking Refuge Turning More Americans Against Undocumented Immigrants?

A look at Pew Research Center survey data collected in February and July of this year.


July 29 • 2:00 PM

Under Water: The EPA’s Ongoing Struggle to Combat Pollution

Frustration and inaction color efforts to enforce the Clean Water Act.


July 29 • 12:40 PM

America’s Streams Are Awash With Pesticides Banned in Europe

You may have never heard of clothianidin, but it’s probably in your local river.


July 29 • 12:00 PM

Mining Your Genetic Data for Profit: The Dark Side of Biobanking

One woman’s personal story raises deep questions about the stark limits of current controls in a nascent industry at the very edge of the frontier of humans and technology.


July 29 • 11:23 AM

Where Should You Go to College?


July 29 • 10:29 AM

How Textbooks Have Changed the Face of War

War is more personal, less glorious, and more hellish in modern textbooks than in the past. But there’s still room for improvement.


July 29 • 10:00 AM

The Monolingual American: Why Are Those Outside of the U.S. Encouraging It?

If you are an American trying to learn German in a large German town or city, you will mostly hear English in return, even when you give sprechen your best shot.


July 29 • 8:00 AM

The Elusive Link Between Casinos and Crime

With a study of the impact of Philadelphia’s SugarHouse Casino, a heated debate gets fresh ammunition.


July 29 • 6:00 AM

What Are the Benefits of Locking Yourself in a Tank and Floating in Room-Temperature Saltwater?

After three sessions in an isolation tank, the answer’s still not quite clear.


July 29 • 4:00 AM

Harry Potter and the Battle Against Bigotry

Kids who identify with the hero of J.K. Rowling’s popular fantasy novels hold more open-minded attitudes toward immigrants and gays.


July 29 • 2:00 AM

Geographic Scale and Talent Migration: Washington, D.C.’s New Silver Line

Around the country, suburbs are fighting with the urban core over jobs and employees.


July 28 • 4:00 PM

Border Fences Make Unequal Neighbors and Enforce Social Inequality

What would it look like if you combined Israel, the West Bank, and Gaza, demographically speaking? What about the United States and Guatemala?


July 28 • 2:00 PM

Are Patient Privacy Laws Being Misused to Protect Medical Centers?

A 1996 law known as HIPAA has been cited to scold a mom taking a picture of her son in a hospital, to keep information away from police investigating a possible rape at a nursing home, and to threaten VA whistleblowers.


July 28 • 12:00 PM

Does Internet Addiction Excuse the Death of an Infant?

In Love Child, documentary filmmaker Valerie Veatch explores how virtual worlds encourage us to erase the boundary between digital and real, no matter the consequences.


Follow us


Subscribe Now

The Rise of the Nuisance Flood

Minor floods are afflicting parts of Maryland nearly 10 times more often than was the case in the 1960s.

America’s Streams Are Awash With Pesticides Banned in Europe

You may have never heard of clothianidin, but it's probably in your local river.

How Textbooks Have Changed the Face of War

War is more personal, less glorious, and more hellish in modern textbooks than in the past. But there’s still room for improvement.

NASA Could Build Entire Spacecrafts in Space Using 3-D Printers

This year NASA will experiment with 3-D printing small objects in space. That could mark the beginning of a gravity-free manufacturing revolution.

The Most Popular Ways to Share Good and Bad Personal News

Researchers rank the popularity of all of the different methods we have for telling people about our lives, from Facebook to face-to-face.

The Big One

One in two full-time American fast-food workers' families are enrolled in public assistance programs, at a cost of $7 billion per year. July/August 2014

Copyright © 2014 by Pacific Standard and The Miller-McCune Center for Research, Media, and Public Policy. All Rights Reserved.